submit urlsubmit rss feedadd directoryphysician directoryPharmacology employment

article

Basic Information (Chemical, Pharmacological, Marketing Data)


Eptifibatide (Integrilin®, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an anti-coagulant that selectively blocks the platelet glycoprotein IIb/IIIa receptor. It reversibly binds to platelets and has a short half-life. Eptifibatide is the third inhibitor of GPIIb/IIIa that has found broad acceptance after the specific antibody Abciximab and the non-peptid Tirofiban entered the global market. The Eptifibatide molecule constitutes a cyclic heptapeptide and belongs to the class of the so called arginin-glycin-aspartat-mimetics.

The drug is sold in two strengthes : vials containing 2mg/ml (20mg totally) and 0.75mg/ml (75mg totally).

More on [ Eptifibatide ]


directory of related categories

 
Eptifibatide RSS feed
Eptifibatide - Twitter Search

Use of enoxaparin and eptifibatide in patients on dialysis was associated with a greater risk of bleeding http://tiny.cc/zXImH
sbhci_org_br (SBHCI) Wed, 16 Dec 2009 23:12:12 -0000
Use of enoxaparin and eptifibatide in patients on dialysis was associated with a greater risk of bleeding http://tiny.cc/zXImH

 
Subscribe to Eptifibatide RSS feed

directory of related sites

Integrilin Consumer Information - FDA - Patient FAQ in html format with a link to approved labeling in pdf format.

Eptifibatide related videos

 

HOMEADVERTISINGABOUT US

articlesartsbusinesscomputersgameshealthhospitalshomekids & teensnewsmobilephysiciansrecreationreferenceregionalscienceshoppingsocietysportsworld


Submit a Site About Become an Editor